Compare CALM & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALM | IRON |
|---|---|---|
| Founded | 1957 | 2017 |
| Country | United States | United States |
| Employees | 4909 | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 1996 | 2020 |
| Metric | CALM | IRON |
|---|---|---|
| Price | $67.19 | $65.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $92.00 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 819.5K | 475.2K |
| Earning Date | 04-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.63 | N/A |
| Revenue | ★ $2,911,632,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $283.52 |
| P/E Ratio | $10.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $66.62 | $40.00 |
| 52 Week High | $96.59 | $99.50 |
| Indicator | CALM | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 21.28 | 24.60 |
| Support Level | N/A | $58.30 |
| Resistance Level | $80.00 | $72.68 |
| Average True Range (ATR) | 1.90 | 2.86 |
| MACD | -0.48 | -0.66 |
| Stochastic Oscillator | 7.98 | 5.34 |
Cal-Maine Foods Inc is an egg company in the U.S. Its shell egg portfolio includes conventional, specialty, cage-free, nutritionally enhanced, organic, brown, pasture-raised, and free-range eggs. The Company operates through the Conventional Shell Eggs, Specialty Shell Eggs and Prepared Foods segments, with Conventional Shell Eggs generating maximum revenue. The Conventional Shell Eggs segment consists mainly of the production, grading, packaging, marketing and distribution of conventional shell eggs, including Sunups and Sunny Meadow. The Company sells its products to grocery store chains, club stores, independent supermarkets, and foodservice distributors serving restaurants, convenience stores, healthcare and education facilities, and hotels throughout the U.S.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.